VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 100 filers reported holding VERONA PHARMA PLC in Q3 2023. The put-call ratio across all filers is 3.08 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,103,617 | -23.9% | 190,406 | -1.3% | 0.02% | -31.4% |
| Q2 2023 | $4,078,265 | -39.5% | 192,917 | -42.5% | 0.04% | -46.2% |
| Q1 2023 | $6,740,856 | -38.5% | 335,700 | -20.0% | 0.06% | -28.6% |
| Q4 2022 | $10,969,296 | +1719.1% | 419,797 | +611.5% | 0.09% | +1720.0% |
| Q3 2022 | $603,000 | +165.6% | 59,000 | +8.7% | 0.01% | +150.0% |
| Q2 2022 | $227,000 | -22.3% | 54,300 | -7.0% | 0.00% | -33.3% |
| Q1 2022 | $292,000 | -25.1% | 58,400 | +0.7% | 0.00% | -25.0% |
| Q4 2021 | $390,000 | +21.5% | 58,000 | -1.0% | 0.00% | +33.3% |
| Q3 2021 | $321,000 | -15.7% | 58,600 | +0.7% | 0.00% | -25.0% |
| Q2 2021 | $381,000 | -19.3% | 58,200 | +3.0% | 0.00% | -33.3% |
| Q1 2021 | $472,000 | +41.3% | 56,500 | +18.2% | 0.01% | +50.0% |
| Q4 2020 | $334,000 | -1.8% | 47,800 | -12.5% | 0.00% | -33.3% |
| Q3 2020 | $340,000 | – | 54,600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,332,485 | $34,817,833 | 22.99% |
| Abingworth LLP | 2,457,500 | $64,214,475 | 20.92% |
| Fairmount Funds Management LLC | 2,875,526 | $75,137,494 | 11.92% |
| Octagon Capital Advisors LP | 2,468,000 | $64,488,840 | 10.04% |
| NEA Management Company, LLC | 5,584,753 | $145,929,596 | 8.20% |
| Knoll Capital Management, LLC | 95,391 | $2,492,567 | 5.62% |
| Frazier Life Sciences Management, L.P. | 2,815,720 | $73,574,764 | 4.57% |
| Resolute Capital Asset Partners LLC | 185,992 | $4,860 | 4.34% |
| Caligan Partners LP | 183,064 | $4,783,462 | 3.98% |
| Samsara BioCapital, LLC | 695,001 | $18,160,376 | 3.91% |